CTP-354 / Cipla, Sun Pharma - LARVOL DELTA

UBS starts Concert Pharmaceuticals (CNCE) at buy (Streetinsider.com) - "UBS initiated coverage on Concert Pharmaceuticals (NASDAQ: CNCE) with a Buy rating and a price target of $25.00...The company is currently developing its two wholly-owned assets, CTP-354 (for spasticity associated with multiple sclerosis and spinal cord injury) and CTP-499..."

Commercial • Multiple Sclerosis